Real-world antibiotic needs for resistant Gram-negative infections
More than 2·8 million antibiotic-resistant infections occur in the USA every year and more than 35 000 people die as a result, with estimated costs exceeding US$2 billion. Resistance in Gram-negative bacteria is increasing, particularly in certain populations at high risk. Over half of the antimicrobial resistance threats highlighted by the Centers for Disease Control and Prevention (CDC) are Gram-negative bacteria, including three of five urgent threats. Since resistance in Gram-negative bacteria is often mediated by plasmids carrying multiple resistance genes, treatment is frequently restricted to second-line and third-line antibiotics with high toxicity or poor efficacy, which causes patient harm and increases health care costs.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.